Skip to main content

Table 3 Clinical characteristics of patients with primary cervical lymphoma of DLBCL subtype (N = 113)

From: Advanced Ann Arbor stage and age over 60 years as prognostic predictors in patients with primary cervical lymphoma: a retrospective cohort study and systematic review

Clinical characteristics

Number (Percentile)

Age (Mean/Median, y)

49.5 ± 16.3/49.0 (20–85)

Time of follow-up (Mean/Median, y)

4.7/3.0 (0.08–20.50)

Elevated LDH (N = 20)

12 (60%)

Ann Arbor Stage

 IE

73 (64.6%)

 IIE

25 (22.1%)

 IIIE

4 (3.5%)

 IVE

11 (9.7%)

Cancer-directed surgery (CDS)

31 (27.4%)

Chemotherapy/Radiotherapy details

 No chemotherapy or radiotherapy

6 (5.3%)

 Chemotherapy alone

57 (50.4%)

  CHOP

17

  CHOP + CDS

9

  R-CHOP

13

  R-CHOP + CDS

7

 Radiotherapy alone

13 (11.5%)

 Radiotherapy + chemotherapy

37 (32.7%)

  Radiotherapy + CHOP

16

  Radiotherapy + CHOP + CDS

1

  Radiotherapy + R-CHOP

13

  Radiotherapy + R-CHOP + CDS

1

Clinical outcomes

 No evidence of disease

93 (82.3%)

 Alive with disease

6 (5.3%)

 Die of the disease

11 (9.7%)

 Die of the other disease

3 (2.7%)

  1. Abbreviations: LDH lactate dehydrogenase, DLBCL diffuse large B-cell lymphoma, (R)-CHOP (Rituximab)-cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone